- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01922583
AUY922 in Patient With Stage IV NSCLC (NSCLC)
A Multi-center Phase II Study of AUY922 in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) With Driver Molecular Alterations Other Than Sensitive EGFR Mutation, Who Have Progressed After One Line of Systemic Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Design:
This is an open-label, single-arm, multicenter phase II trial in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC (n = 9 x 7)
Objectives:
Primary objective(s):
To define the objective response rate by RECIST 1.1 of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC
Secondary objective(s):
(1) To define the disease control rate (complete response + partial response + stable disease >=24 weeks) of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC. (2) To determine the progression-free survival of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, KRAS, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC. (3) To determine the overall survival of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, KRAS, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC.
Exploratory Objective(s):
To study the pharmacodynamics of circulating tumor cells and plasma proteins.
Planned number of subjects: A total of 63 patients for the first stage of this study in 1 - 3 centers in Taiwan.
Patient population:
- Stage IV (by AJCC 7th edition) NSCLC.
- EGFR T790M mutation; EGFR exon 20 and other uncommon mutation; HER2 mutation; BRAF mutation; ALK translocation; ROS1 translocation; or RET translocation in tumor samples.
- One line of prior systemic therapy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Tainan, Taiwan, 70403
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital
-
Taipei, Taiwan, 100
- Department of Oncology, National Taiwan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically proven diagnosis of stage IV NSCLC (AJCC 7th) which had been treated with one systemic therapy.
One of the molecular alterations as follows:
- EGFR mutations in exon 20 T790M.
- EGFR mutations in exon 20; in-frame duplication and/or insertion (e.g. A767_V769dupASV or H773_V774insH) or point mutations other than T790M; or other uncommon mutations.
- HER2 mutation in exon 20; in-frame duplication and/or insertion (e.g. YVMA 776-779 ins).
- BRAF mutation in exon 15; point mutation (e.g. V600E) or in exon 11; point mutation (e.g. G469A, D594G).
- ALK translocation resulting in EML4-ALK, KIF5B-ALK, or TFG-ALK fusion as determined by an ALK break apart FISH assay and defined by an increase in the distance of 5' and 3' ALK probes (split 5'-3') or the loss of the 5' probe (single 3'). Positive ALK results from other methods such as immunohistochemistry (IHC) or reverse transcriptase polymerase chain reaction testing may also be acceptable.
- ROS1 translocation resulting in CD74-ROS1 or SLC34A2-ROS1, etc.
- RET translocation resulting in KIF5B-RET fusion, etc.
- Patients with brain metastases are eligible if treated and neurologically stable for at least 2 weeks and is not taking any steroid.
- Any prior chemotherapy, targeted therapy (monoclonal antibodies), or major surgeries must have had completed at least 4 weeks before initiation of study medication. Any prior targeted therapy (tyrosine kinase inhibitors), radiotherapy or minor surgeries must have had completed at least 2 weeks before initiation of study medication. Any acute toxicity must have recovered to <=grade 1 (except for alopecia).
- Patients must have measurable or evaluable disease as per RECIST version 1.1.
- 20 years of age or older
- ECOG performance status 0-2
Adequate organ function as defined by the following criteria:
- Bone marrow function
- Hemoglobin >=8.0 g/dL
- Absolute neutrophil count (ANC) >=1500/uL
- Platelets >=100,000/uL
- Hepatic function
- Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) <=3.0 x upper limit of normal (ULN) or AST and ALT <=5.0 x ULN if there is liver metastasis
- Total serum bilirubin <=1.5 x ULN Renal function
- Creatinine <= 1.5 x ULN or creatinine clearance >=45 mL/min
- Able to communicate well with the investigator, to understand and comply with the requirements of the study. Understand and sign the written informed consent.
- Patients must use effective methods of contraception during the study period and for at least 90 days following study completion (excluding surgically sterile male patients, surgically sterile or postmenopausal female patients).
Exclusion Criteria:
- Currently on other therapeutic clinical trials
- Prior treatment of HSP90 inhibitors
Any of the following within 3 months before initiation of study medication
- Myocardial infarction
- Unstable angina
- Coronary artery bypass graft
- Congestive heart failure NYHA functional class III or IV
- Cerebral vascular accident
- Transient ischemic attack
- Uncontrolled hypertension at screening
- Ongoing cardiac arrhythmias of NCI CTCAE grade >=2
- Active infection requiring antibiotics
- Pregnancy or breast feeding
- Prior malignancy within the past 5 years (excluding non-melanoma skin cancer, cervical carcinoma in situ, superficial bladder cancer, and early prostate cancer).
- Active hepatitis B or C; positive HIV test result.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vial
AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
|
AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate
Time Frame: Patients will be followed up for 2 years(post disease progression)
|
To define the by RECIST 1.1 of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC
|
Patients will be followed up for 2 years(post disease progression)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy, progression-free survival (PFS)
Time Frame: Patients will be followed up for PFS and OS for 2 years.(post disease progression)
|
Patients will be followed for progression-free survival (PFS) and overall survival (OS) which will be analyzed by using a Kaplan-Meier curve. Patients will be followed up for PFS and OS for 2 years. |
Patients will be followed up for PFS and OS for 2 years.(post disease progression)
|
overall survival (OS)
Time Frame: Patients will be followed up for OS for 2 years.(post disease progression)
|
Patients will be followed for overall survival (OS)
|
Patients will be followed up for OS for 2 years.(post disease progression)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Chih-Hsin Yang, MD, PhD, National Taiwan University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAUY922ATW02T(201302063MIPD)
- 1020009413 (Other Identifier: Taiwan Food and Drug Administration (TFDA))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer (NSCLC)
-
H. Lee Moffitt Cancer Center and Research InstituteNestle Health ScienceWithdrawnNSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | NSCLC Stage IIIB | Non-small Cell Lung Cancer Stage IIIB | NSCLC, Stage IIIA | Non-small Cell Lung Cancer Stage ⅢAUnited States
-
ElephasBeaufort CRORecruitingNSCLC | Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Metastatic NSCLC - Non-Small Cell Lung CancerUnited States
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
Jun Zhang, MD, PhDGenentech, Inc.; ExelixisNot yet recruitingLung Cancer | NSCLC Stage IV | Advanced NSCLC | Metastatic NSCLC - Non-Small Cell Lung CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingNSCLC | Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Non-small Cell CarcinomaUnited States
-
University of Alabama at BirminghamSanofiCompletedNon-small Cell Lung Cancer (NSCLC) | Metastatic NSCLC | Stage IV NSCLCUnited States
-
Oslo University HospitalAstraZenecaActive, not recruitingCancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage IIINorway, Finland, Lithuania, Estonia
-
Radiotherapy Oncology Centre "Santa Maria" HospitalPaola Anselmo,MD; Michelina Casale,PhD; Fabio Trippa,MDRecruitingNSCLC | Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Oligometastatic Disease | Non-Small Cell Squamous Lung Cancer | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Non-Small Cell Adenocarcinoma and other conditionsItaly
-
Heather WakeleeNovartis; Genentech, Inc.TerminatedNon-small Cell Lung Cancer (NSCLC), Recurrent | Non-small Cell Lung Cancer (NSCLC), Stage IVUnited States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
Clinical Trials on AUY922
-
Novartis PharmaceuticalsCompleted
-
M.D. Anderson Cancer CenterNovartisTerminated
-
Massachusetts General HospitalCompletedNon Small Cell Lung CancerUnited States
-
SCRI Development Innovations, LLCNovartisCompletedGastrointestinal Stromal TumorUnited States
-
Dale Shepard, MD, PhDNational Cancer Institute (NCI)TerminatedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Novartis PharmaceuticalsCompletedStomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 ProteinTaiwan, Switzerland, Korea, Republic of, Germany, United States, Japan
-
Novartis PharmaceuticalsCompletedBreast Cancer | Hematologic NeoplasmsNetherlands, Switzerland, United Kingdom, United States
-
Massachusetts General HospitalCompleted
-
University Health Network, TorontoNovartis PharmaceuticalsTerminatedAdenocarcinoma of the Pancreas | Metastatic DiseaseCanada
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsUnknownGastrointestinal Stromal TumorTaiwan